Ainuovirine vs Emtricitabine (Emtriva)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Ainuovirine
Marketed by Jiangsu Aidea Pharmaceutical Group under a licence from Kainos Medicine
NCT01348516 · Phase 1 · completed
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source. Its registered primary outcome on ClinicalTrials.gov is "Safety/ Tolerability Evaluation". Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: June 2028 · NCT07631897 (registry estimate)
Reported efficacy
Safety/ Tolerability Evaluation (participants will be followed for the duration of hospital stay, 8-10 days for SAD and 14-16 days for MAD): In 80 healthy male volunteers given single or multiple doses (once daily for 7 days) of 75, 150, 300 or 600 mg or placebo, the drug was generally well tolerated with no serious adverse events and showed dose- and time-dependent nonlinear pharmacokinetics across the 75 to 600 mg range.
Result source: NCT01348516
Emtricitabine (Emtriva)
Marketed by Gilead Sciences and partners
NCT00112047 · Phase 3 · completed
The trial randomized 517 participants to an active comparator, but treatment was open-label rather than double-blinded. Its hard clinical virologic endpoint was met: 84.4% versus 72.8% achieved confirmed HIV-1 RNA below 400 copies/mL at week 48 (p=0.002; 95% CI for the difference, 4.3% to 18.6%), supporting non-inferiority and a favorable result, but the lack of blinding limits the evidence strength.
Next expected readout: June 2029 · NCT07792096 (registry estimate)
Reported efficacy
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants (met)
Result source: NCT00112047
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ainuovirine | Emtricitabine (Emtriva) |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not reported | —Not posted · NCT00002416 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not reported | —Not posted · NCT00002416 |
| CD4 count, change (week 48) | —Not reported | —Not posted · NCT00002416 |
HIV-1 RNA below 50 copies/mL (week 48)
- Ainuovirine
- —Not reported
- Emtricitabine (Emtriva)
- —Not posted · NCT00002416
HIV-1 RNA 50 copies/mL or more (week 48)
- Ainuovirine
- —Not reported
- Emtricitabine (Emtriva)
- —Not posted · NCT00002416
CD4 count, change (week 48)
- Ainuovirine
- —Not reported
- Emtricitabine (Emtriva)
- —Not posted · NCT00002416
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Ainuovirine: no structured comparison results are available for HIV.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ainuovirine's landscape · Emtricitabine (Emtriva)'s landscape